Other studies have also shown that the presence of KRAS mutations is a poor prognostic factor both in colorectal cancer in general and specifically in patients with colorectal lung metastases [16, 18, 19], although this may be partly due to patients with RAS mutations being unsuitable for treatment with anti-EGFR monoclonal antibodies. Here, KRAS is linked to colorectal cancer.